Navigation Links
VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007
Date:10/29/2008

$23.1 Million Net Revenues, $0.10 Net Income Per Share

SAN JOSE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS), a leading provider of medical devices for the minimally invasive treatment of venous disease, today announced its financial results for the third quarter ended September 30, 2008.

Net revenues for the third quarter of 2008 increased 32% to $23.1 million compared with $17.5 million for the third quarter of 2007. Net revenues for the third quarter of 2008 included net product revenues and royalty revenues. Net product revenues are derived from the sale of disposable endovenous catheters and devices, RF generators and accessory products. Royalty revenues are derived from other companies paying royalties for a license to certain VNUS patents previously subject to an infringement lawsuit.

Net product revenues for the third quarter of 2008 increased 25% to $21.9 million compared with $17.5 million for the third quarter of 2007. Net product revenues increased sequentially by 2% when compared to net product revenues in the second quarter of 2008 of $21.5 million. The increase in net product revenues from the third quarter of 2007 was due to continuing higher sales of disposable ClosureFAST(TM) catheters and higher overall international sales. Disposable catheters and device unit sales increased in the third quarter of 2008 by 29% compared to the third quarter of 2007.

Royalty revenues in the third quarter of 2008 were $1.2 million. The royalty revenues are a result of an agreement entered into on June 3, 2008, resolving the infringement lawsuit against two companies selling laser vein ablation products. In the third quarter of 2008, the royalty revenues als
'/>"/>

SOURCE VNUS Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. District Court Sides with Smith & Nephew; Rules that It will Issue Injunction that will Prohibit Arthrex Inc. from Selling Infringing Medical Devices
2. The Lancets New Online Medical Journal Helps Clinicians and Medical Researchers Find Practice-Changing Evidence Quickly and Easily
3. Inverness Medical Innovations Announces Third Quarter 2008 Results
4. Environmental Tectonics Corporations BioMedical Systems Division Places Two Monoplace Chambers at East Orange (NJ) General Hospital
5. Balan Biomedical, Inc. Announces the Formation of Battery Consulting Group
6. China Medical Technologies Announces Reporting Dates for the September Quarter Results and Addresses Investor Inquiries
7. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET October 29, 2008 to Discuss Third Quarter 2008 Results
8. StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists
9. Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado
10. HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City
11. Bio-Pharma Industry Improves Patient Outcomes Through Continuing Medical Education (CME)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 DTS Language Services, Inc . ... Portal for Life Science organizations who need document translations. ... matter of their documents in advance with a selection of ... of translations, often a critical factor in clinical and scientific ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... China, Feb. 12 /PRNewswire-Asia-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC ... company with its principal operations,in the People,s Republic of ... call at 9:00 a.m. Eastern on Tuesday, February 17, ... December 31, 2008 of,its fiscal year 2009. , ...
... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), ... http://www.cordblood-america.com ) focused on bringing the life saving potential ... pleased to announce that between January 1, 2009, and ... approximately $1 million.The Company previously said in press releases ...
... (NYSE Alternext US: PTN) will announce its second quarter, ... 2009 before the open of the U.S. financial markets.Palatin ... webcast hosted by its executive management team on February ... of operations in greater detail and an update on ...
Cached Biology Technology:Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009 2Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009 3Cord Blood Announces $1 Million Reduction in Long Term Debt 2Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009 2
(Date:7/9/2014)... Cholinergic inhibitors and N-methyl-D-aspartate receptor antagonists can ... fail to affect irreversible cognitive dysfunction and ... brain. Amyloid beta peptide (Aβ) vaccines reduced ... disease (AD) transgenic mouse model, and significantly ... Cao and his team, First Affiliated Hospital ...
(Date:7/9/2014)... copy of its DNA, a fundamental step in the life ... in the human body. While scientists have had an idea ... enzymes that unzip the double-stranded DNA and create "daughter" copiesthey ... works. , Now, researchers at Rockefeller University have built the ... "replication fork"the point where DNA is split down the middle ...
(Date:7/8/2014)... is an increased risk of severe perineal tearing during childbirth ... delivery, suggests a new study published today (9 July) in ... (BJOG). , This study, investigates among women who have had ... delivery in subsequent pregnancies and the recurrence of severe perineal ... childbirth and in some women the tear may be more ...
Breaking Biology News(10 mins):Rockefeller scientists first to reconstitute the DNA 'replication fork' 2Rockefeller scientists first to reconstitute the DNA 'replication fork' 3Rockefeller scientists first to reconstitute the DNA 'replication fork' 4Mode of delivery following a perineal tear and recurrence rate in subsequent pregnancies 2
... carry out one of the most remarkable forms of feeding ... extending its stomach out of its mouth and over the ... The prey tissue is partially digested externally before the soup-like ... , The researchers at Queen Mary, University of London and ...
... of breast cancer, termed estrogen receptor positive or ER+, ... each year. Research by scientists at the HudsonAlpha ... Birmingham Comprehensive Cancer Center aims to provide physicians a ... "Can we find something in the genome that correlates ...
... shape based on environment, fending off attackers or ... worked toward mimicking similar biological responses in non-living ... the medical arena. Now, researchers at ... biomimetic response using hydrogelsa material that constitutes most ...
Cached Biology News:Scientists uncover secrets of starfish's bizarre feeding mechanism 2HudsonAlpha and UAB researchers work to identify optimal treatments for ER+ breast cancer 2Light that moves and molds gels 2
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
...
All-in-one mix, removes primers and dNTPs from PCR product for following direct sequencing...
Biology Products: